Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash from Investing Activities (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Cash from Investing Activities for 9 consecutive years, with $4.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Investing Activities fell 75.42% year-over-year to $4.7 million, compared with a TTM value of $32.4 million through Jun 2025, up 169.12%, and an annual FY2025 reading of $37.4 million, up 59.93% over the prior year.
  • Cash from Investing Activities was $4.7 million for Q2 2025 at VYNE Therapeutics, down from $19.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $19.8 million in Q1 2025 and bottomed at -$62.4 million in Q4 2023.
  • Average Cash from Investing Activities over 5 years is $600916.7, with a median of $2.9 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities tumbled 6235500.0% in 2023, then soared 655.65% in 2025.
  • Year by year, Cash from Investing Activities stood at $1.0 million in 2021, then crashed by 99.9% to $1000.0 in 2022, then crashed by 6235500.0% to -$62.4 million in 2023, then surged by 120.43% to $12.7 million in 2024, then plummeted by 63.3% to $4.7 million in 2025.
  • Business Quant data shows Cash from Investing Activities for VYNE at $4.7 million in Q2 2025, $19.8 million in Q1 2025, and $12.7 million in Q4 2024.